Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Interprofessional Communication |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
|
FDA is now requiring prescribing information for Reclast (zoledronic acid injection, Novartis) to include a warning against use of the drug by patients with renal dysfunction. Read full article. |
 |
|
|
 |
A monthly review of the
peer-reviewed literature by
Drug Topics' Editorial Advisor
Anna D. Garrett, PharmD, BCPS. Anna Garrett is manager, Outpatient Clinical Pharmacy Programs, Mission Hospital, Asheville, N.C.
|
Do PPIs interact with aspirin?
Read full article.
|
People who carry more weight for a longer period of time are at a greater risk of developing type 2 diabetes, a new study has reported. Read full article. |
|
An interaction between warfarin and acetaminophen may result in significant elevations of international normalized ratio (INR), putting patients at increased risk for hemorrhagic complications. Read full article. |
|
Nonsteroidal anti-inflammatory drugs should be used with caution during pregnancy, as exposure may increase the risk of spontaneous abortion. Read full article. |
|
FDA has approved an antipsychotic medication, haloperidol injection, USP (Sagent Pharmaceuticals), for use in the treatment of schizophrenia and to control symptoms of Tourette's disorder. Read full article. |
|
An FDA advisory panel has recommended approval of the anticoagulant rivaroxaban (Xarelto, Johnson & Johnson and Bayer AG) for use in prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Read full article. |
 |
Meetings and Events
September 26-27, 2011 2nd Annual Pharmaceutical Labeling Summit
Washington, D.C.
Contact:
Jeff Grizzel, Conference Director
FDA News
300 N. Washington St., #200
Falls Church, VA 22046-3431
703-538-7668
[email protected]
www.fdanews.com/PharmaLabeling
October 16-19 ACCP Annual Meeting
Pittsburgh, Pa.
Contact:
http://www.accp.com/meetings/am11/
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
